SCHEMBL19236510

SCHEMBL19236510

Nc1nc2n[nH]cc2c(=O)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.49
▸ PNP P00491 3/20 0.48
▸ THRB P10828 2/20 0.47
▸ MITF O75030 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ HBB P68871 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ QTRT1 Q9BXR0 1/20 0.46
▸ DYRK1A Q13627 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ FGFR1 P11362 2/20 0.39
▸ FGFR2 P21802 2/20 0.39
▸ TYMS P04818 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxypurinol SCHEMBL8258215 0.77 PARP1 (0.38) CYP1A2QTRT1KDM4EALDH1A1HPGD
SCHEMBL8278866 0.77 PARP1 (0.46) CYP1A2MAPTKDM4EALDH1A1HPGD
SCHEMBL19236511 0.69 MITF (0.47) PNPTHRBMITFTP53ALOX15
SCHEMBL13833239 0.67 KDM4E (0.49) CYP1A2PNPTHRBMITFTP53
SCHEMBL10984818 0.67 HCAR2 (0.59) QTRT1FGFR1TYMS
SCHEMBL5144478 0.67 ADORA2A (0.44) —
SCHEMBL31591432 0.66 NPC1 (0.50) CYP1A2ALOX15HIF1AMAPTKDM4E
8-Aminoguanine SCHEMBL21761 0.66 PNP (1.00) PNPTHRBMITFTP53ALOX15
SCHEMBL1014919 0.65 PDPK1 (0.39) —
SCHEMBL481407 0.65 DYRK1A (0.53) CYP1A2PNPQTRT1DYRK1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 — — EP disclosed
EP-3925956-A1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BioCryst Pharmaceuticals, Inc. (US) 2021-12-22 — — EP disclosed
EP-3411411-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2021-05-19 — — EP disclosed
WO-2017136395-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2017-08-10 — — WO disclosed
Send feedback